Monte Rosa Therapeutics, Inc. — Q3 2022 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2022. Monte Rosa is a clinical-stage biotechnology company developing small-molecule molecular glue degraders using its QuEEN platform. It reported no product revenue; operations are funded principally through equity financing.
Financial performance
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $21.3m | $15.1m | $60.2m | $39.0m |
| General and administrative expense | $7.0m | $4.8m | $19.7m | $10.5m |
| Total operating expenses / operating loss | $28.4m | $19.9m | $79.9m | $49.5m |
| Net loss | $27.3m | $19.8m | $77.7m | $50.5m |
| Net loss per share, basic and diluted | $0.58 | $0.43 | $1.67 | $2.85 |
With no reported revenue, profit and operating margins are not meaningful. Q3 operating expenses rose $8.5m year over year, and nine-month expenses rose $30.4m. Management attributed the increases mainly to expanded R&D activity, headcount, facilities and related costs. Nine-month R&D spending included $24.8m of external services and $19.4m of personnel costs.
Cash, liquidity and balance sheet
- At September 30, cash and cash equivalents were $112.4m and marketable securities were $159.8m, totaling $272.1m. Including $5.3m of restricted cash, cash, equivalents, restricted cash and marketable securities totaled $277.4m.
- Nine-month operating cash use was $68.5m, compared with $45.2m in 2021. Investing cash use was $165.3m, mainly reflecting $290.0m of securities purchases, partly offset by $130.3m of maturities. Financing cash provided was $0.03m; the comparable 2021 period included IPO and preferred-stock proceeds.
- At quarter-end, total liabilities were $66.5m and stockholders’ equity was $291.1m. No credit facility or committed financing source was reported. Operating lease liabilities totaled $45.7m, including $3.1m current.
- The company sold 1,638,226 shares through an ATM offering on September 30 for $13.9m gross and $13.2m net; proceeds were receivable at quarter-end and received October 5.
Outlook, risks and notable items
- Management expected available cash, cash equivalents and marketable securities to fund operating expenses and capital requirements for at least 12 months from issuance of the interim financial statements. It also stated that further financing will be needed for future discovery, preclinical and clinical work. The estimate depends on assumptions and may not be sufficient if plans or costs change.
- The company planned to initiate a clinical trial of MRT-2359 for Myc-driven and selected other solid tumors in Q4 2022. It also described ongoing preclinical and discovery work, including GSPT1, NEK7, CDK2, VAV1, BCL11A and sickle cell disease targets. Development timing, costs and outcomes remain uncertain.
- Management expects R&D, G&A and capital expenditures to increase. Additional equity financing could dilute shareholders; debt or other financing may not be available on acceptable terms. The company has no commercial products and expects continuing losses.
- Available-for-sale securities had $0.7m of aggregate unrealized losses at quarter-end. Management attributed the declines primarily to market conditions, reported no individual significant unrealized loss, and did not expect or intend to sell securities before recovery.
- Disclosure controls and procedures were deemed ineffective. Previously identified material weaknesses in financial-reporting controls had not been remediated by September 30, 2022; remediation efforts were ongoing.
- The company reported no material legal proceedings, no material changes to previously disclosed contractual commitments, and no off-balance-sheet arrangements. COVID-19 had not significantly affected financial condition or operations to date, though future effects were uncertain.
Important facts for investors to verify
- Whether MRT-2359’s planned Q4 2022 trial began as expected and what subsequent clinical milestones or results have been disclosed.
- Cash burn, securities and restricted-cash balances, and whether the stated 12-month runway remains valid as R&D and facility spending grow.
- Further ATM or other financing activity, share-count changes and potential dilution.
- Progress and testing of controls remediation, given the disclosed material weaknesses and ineffective disclosure controls.
- Lease obligations and the timing and cost of the Harrison Avenue laboratory build-out, including tenant-improvement reimbursements.